JNJJanssen Research & Development, LLCSigning up patients
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Jun 4, 2025
- Main results expected
- Jun 22, 2029
- Fully finished
- Aug 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants who Achieve Complete Remission (CR)
Measured over: Up to 4 years and 1 month
Overall Survival (OS)
Measured over: Up to 4 years and 1 month
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06852222 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC